Jonathan Yang
Radiation Oncology · New York, NYNPI 1821387606
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,570 of the $14,617 with a category attached, or 99.7%. Bayer accounts for 78.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $11,420 and has fallen 99.6% since, to $47 in 2025. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3 payments — averaging $4872.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$11K
- Astrazeneca UK Limited$3K
- Servier Pharmaceuticals LLC$47
Across 26 payments — averaging $35,834 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$932K
What the payments were for
- Consulting fees$14,570100%
- Food & beverage$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 1 | $11,420 |
| Astrazeneca UK Limited | 1 | $3,150 |
| Servier Pharmaceuticals LLC | 1 | $47 |
How this compares
$14,617 in reported general payments places this provider in the 90th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexamethasone | 24 | $238 |
| Memantine Hcl | 11 | $168 |
| Methylprednisolone | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in New York
- Michael ZelefskyNew York$946K
- Nancy LeeNew York$233K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
- Charles SimoneNew York$84K
- Silvia FormentiNew York$57K
- Brandon ImberNew York$44K
- Himanshu NagarNew York$43K
- Chiaojung TsaiNew York$38K
- Christopher BarkerNew York$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.